AmpliPhi Biosciences Corporation Культура компании

Dr. Paul C. Grint, M.D., has been the Chief Executive Officer of AmpliPhi Biosciences Corporation since May 31, 2017. Dr. Grint served as the Chief Executive Officer and President of Regulus Therapeutics Inc. since June 1, 2015 until May 4, 2017 and served as its Chief Medical Officer from June 16, 2014 to June 1, 2015. Dr. Grint has over two decades of experience in biologics and small molecule development, including the successful commercialization of products in oncology, anti-infectives and immunology. Prior to Regulus, Dr. Grint served as the President at Cerexa, Inc. and was responsible for the oversight of Anti-Infective product development. Prior to joining Cerexa, he served as Senior Vice President at Forest Research Institute, Inc. He served as the Chief Medical Officer and Head of Development at Kalypsys, Inc. He served as Chief Medical Officer and Senior Vice President of Zephyr Sciences, Inc. Prior to joining Zephyr, Dr. Grint served as Vice President and Head of Clinical Research and Development of Pfizer Inc. in La Jolla. He served in executive level positions at Pfizer Inc., IDEC Pharmaceuticals Corporation and Schering-Plough Corporation. He served as Chief Medical Officer and Senior Vice President of Medical and Clinical Research and Development at Biogen Inc. since January 2001. Prior to joining Biogen, Dr. Grint was employed with Schering-Plough Research Institute from 1992 to 2000 and served as its Vice President of Clinical Immunology and Biotechnology. He has been a Non-Executive Director at AmpliPhi Biosciences Corporation since November 2015. He has been a Director of Numira Biosciences, Inc. since March 2008 and Amplyx Pharmaceuticals, Inc. since May 24, 2016. He serves as a Member of Advisory Board at CovX Research LLC. He served as a Director of Regulus Therapeutics Inc. since June 1, 2015 until May 4, 2017. He served as Member of Scientific Advisory Board at MultiCell Technologies, Inc. He served as a Member of clinical Advisory Board of Tobira Therapeutics, Inc. Dr. Grint served as a Director of Illumina Inc. from April 12, 2005 to May 29, 2013. He serves as Chairman of the Advisory Council of the Keck Graduate Institute. He served as the Chairman of the Biotechnology Therapy Team at St. Bartholomew's Hospital in London. He served as an Honorary Lecturer in the Department of Virology at St. Bartholomew's Hospital in London. Dr. Grint is a Fellow of the Royal College of Pathologists, a member of numerous professional and medical societies and the author or co-author of over fifty scientific publications. Dr. Grint received his Medical Degree from the University of London, St. Bartholomew's Hospital Medical College in London, U.K. He has a B.S. in Medical Science from Barts & The London School of Medicine & Dentistry, Queen Mary University of London.

Dr. Alexander Gaidamaka, Ph.D., D.V.M has been the Vice President of Chemistry, Manufacturing and Control at AmpliPhi Biosciences Corporation since August 2015. Prior to AmpliPhi, Dr. Gaidamaka served as Chief Executive Officer and CSO of Personalized OncoTherapeutics Inc. He has held executive R&D, product development and quality control roles at Pharma Green LLD, Merial, Sanofi Pasteur, Bioniche Life Sciences Inc. and Biopharm JSC. Dr. Gaidamaka was also previously head of the Department of Immunopharmacology & Allergology at the All-Union Research Institute of Drug Chemistry and Technology, Ukraine. He has over 25 years in the life sciences sector. He received a Ph.D. in immunology and microbiology and D.V.M from the Kharkov State Veterinary Academy, Ukraine.

Mr. Steven R. Martin, also known as Steve, has been the Chief Financial Officer of AmpliPhi Biosciences Corporation since January 19, 2016 and has been its Senior Vice President since February 7, 2016. Mr. Martin served as the Chief Financial Officer of Applied Proteomics, Inc. since December 16, 2014 and serves as its Senior Vice President. Mr. Martin served as an Acting Chief Accounting Officer of Cricket Communications, Inc., since February 2008. Mr. Martin served as the Chief Financial Officer and Senior Vice President of Apricus Biosciences, Inc. from June 2011 to December 2014 and served as its Secretary since September 2013 until December 2014. He served as the Principal Accounting Officer and Treasurer of Apricus Biosciences, Inc. until December 2014. He served as the Chief Financial Officer and Senior Vice President of Bakbone Software Inc. since August 21, 2008 and also served as its Principal Accounting Officer. Mr. Martin also served as Interim Chief Executive Officer of Bakbone Software Inc. since April 2010. He served as an Interim Chief Executive Officer of Apricus Biosciences, Inc., from November 2012 to March 2013. He served as an accounting consultant of Cricket Communications, Inc. since October 2007. He is a Senior Finance Professional with more than 30 years of experience in both public accounting and private industry. He served as an Acting Chief Accounting Officer of Leap Wireless International Inc. from February 27, 2008 to June 2008. He served as Vice President and Chief Financial Officer of Stratagene Corporation from July 1, 2005 to September 2007 and served as its Director of Finance from May 2004 to July 2005. He also served as Principal Accounting Officer and Secretary of Stratagene Corporation. He was responsible for integrating the accounting and reporting for all entities in connection with the 2004 merger. From March 2001 to May 2003, Mr. Martin served as Controller of Gen-Probe, Inc. where he was held senior finance positions in three multinational, manufacturing companies. He served as Vice President of Finance at Nuera Communications, Inc. He served as Vice President and Controller at Aldila Golf Corp. He was the President and a member of the Board of Directors of the Financial Executives International San Diego Chapter. Along with strengthening internal controls in the accounting function, his duties also include hiring and training staff to meet the reporting requirements of the Securities and Exchange Commission. He was successful in developing corporate governance programs in support of Stratagene Corp. He worked as a Consultant to Leap since October 2007. Mr. Martin spent ten years with the public accounting firm of Deloitte & Touche LLP, where he served as its Senior Audit Manager. He is a Member of the American Institute of Certified Public Accountants, Financial Executives Institute and American Bioscience Financial Officers. In 2011, he was awarded the San Diego Business Journal's Chief Financial Officer of the Year Award for Medium Public Companies. Mr. Martin is a Certified Public Accountant and holds a Bachelor of Science degree in Accounting from the San Diego State University and a BA from Howard University.

Mr. Michael Scott Salka is a Consultant of AmpliPhi Biosciences Corporation since May 31, 2017. Mr. Salka serves as the Chief Executive Officer of Aspyrian, CendR and Vesper Biologics, all biotechnology companies. Mr. Salka served as the Chief Executive Officer at AmpliPhi Biosciences Corporation since May 18, 2015 until May 31, 2017. He served as the Chief Executive Officer of Ambit Biosciences Corporation from 2001 to 2010. He Co-Founded Sequana Therapeutics, Inc. in early 1993. He served as the Chief Financial Officer of Sequana Therapeutics Inc. since September 1995 and also served as its Vice President of Operations. He played key roles in financing it through private and public stock offerings and in establishing research alliances with Glaxo, Boehringer Mannheim, Boehringer Ingelheim and Parke-Davis. After the sale of Sequana in 1998 and until joining Ambit in January 2001, he served as the President and Chief Executive Officer of two privately-held genomics companies, Arcaris, Inc., and 454 Corporation. He served in various management positions at Burroughs Corporation, Unisys Corporation and The BFGoodrich Company. He also served honorably in the United States Army's Special Forces as an Advisor to several Central American governments on matters of internal defense. He has been a Director of AmpliPhi Biosciences Corporation since May 18, 2015 He has been a Director of BIOCOM, Inc. since 2007 and San Diego State University School of Business since 2009. He served as a Director of Ambit Biosciences Corporation. He served as a Director of Sorrento Therapeutics, Inc. from February 23, 2012 to March 7, 2014 and served as its Member of Scientific Advisory Board. Mr. Salka received his B.S. in Finance from San Diego State University and his M.B.A. from the Carnegie Mellon University.